1
|
The Prognostic Significance of Early Glycemic Profile in Acute Ischemic Stroke Depends on Stroke Subtype. J Clin Med 2023; 12:jcm12051794. [PMID: 36902581 PMCID: PMC10003561 DOI: 10.3390/jcm12051794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Revised: 02/16/2023] [Accepted: 02/19/2023] [Indexed: 02/26/2023] Open
Abstract
It is still unclear whether early glycemic profile after admission for acute ischemic stroke (IS) has the same prognostic significance in patients with lacunar and non-lacunar infarction. Data from 4011 IS patients admitted to a Stroke Unit (SU) were retrospectively analyzed. Lacunar IS was diagnosed by clinical criteria. A continuous indicator of early glycemic profile was calculated as the difference of fasting serum glucose (FSG) measured within 48 h after admission and random serum glucose (RSG) measured on admission. Logistic regression was used to estimate the association with a combined poor outcome defined as early neurological deterioration, severe stroke at SU discharge, or 1-month mortality. Among patients without hypoglycemia (RSG and FSG > 3.9 mmol/L), an increasing glycemic profile increased the likelihood of a poor outcome for non-lacunar (OR, 1.38, 95%CI, 1.24-1.52 in those without diabetes; 1.11, 95%CI, 1.05-1.18 in those with diabetes) but not for lacunar IS. Among patients without sustained or delayed hyperglycemia (FSG < 7.8 mmol/L), an increasing glycemic profile was unrelated to outcome for non-lacunar IS but decreased the likelihood of poor outcome for lacunar IS (OR, 0.63, 95%CI, 0.41-0.98). Early glycemic profile after acute IS has a different prognostic significance in non-lacunar and lacunar patients.
Collapse
|
2
|
Yao M, Hao Y, Wang T, Xie M, Li H, Feng J, Feng L, Ma D. A review of stress-induced hyperglycaemia in the context of acute ischaemic stroke: Definition, underlying mechanisms, and the status of insulin therapy. Front Neurol 2023; 14:1149671. [PMID: 37025208 PMCID: PMC10070880 DOI: 10.3389/fneur.2023.1149671] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2023] [Accepted: 02/21/2023] [Indexed: 04/08/2023] Open
Abstract
The transient elevation of blood glucose produced following acute ischaemic stroke (AIS) has been described as stress-induced hyperglycaemia (SIH). SIH is common even in patients with AIS who have no previous diagnosis of diabetes mellitus. Elevated blood glucose levels during admission and hospitalization are strongly associated with enlarged infarct size and adverse prognosis in AIS patients. However, insulin-intensive glucose control therapy defined by admission blood glucose for SIH has not achieved the desired results, and new treatment ideas are urgently required. First, we explore the various definitions of SIH in the context of AIS and their predictive value in adverse outcomes. Then, we briefly discuss the mechanisms by which SIH arises, describing the dual effects of elevated glucose levels on the central nervous system. Finally, although preclinical studies support lowering blood glucose levels using insulin, the clinical outcomes of intensive glucose control are not promising. We discuss the reasons for this phenomenon.
Collapse
Affiliation(s)
- Mengyue Yao
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Yulei Hao
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Tian Wang
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Meizhen Xie
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Hui Li
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Jiachun Feng
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Liangshu Feng
- Stroke Centre, Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China
- Liangshu Feng
| | - Di Ma
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
- *Correspondence: Di Ma
| |
Collapse
|
3
|
de Oliveira JL, Ávila M, Martins TC, Alvarez-Silva M, Winkelmann-Duarte EC, Salgado ASI, Cidral-Filho FJ, Reed WR, Martins DF. Medium- and long-term functional behavior evaluations in an experimental focal ischemic stroke mouse model. Cogn Neurodyn 2020; 14:473-481. [PMID: 32655711 DOI: 10.1007/s11571-020-09584-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Revised: 02/25/2020] [Accepted: 03/11/2020] [Indexed: 12/16/2022] Open
Abstract
Cerebrovascular accident (CVA) is one of the leading causes of death and disability worldwide, as well as a major financial burden for health care systems. CVA rodent models provide experimental support to determine possible in vivo therapies to reduce brain injury and consequent sequelae. This study analyzed nociceptive, motor, cognitive and mood functions in mice submitted to distal middle cerebral artery (DMCA) occlusion. Male C57BL mice (n = 8) were randomly allocated to control or DMCA groups. Motor function was evaluated with the tests: grip force, rotarod and open field; and nociceptive threshold with von Frey and hot plate assessments. Cognitive function was evaluated with the inhibitory avoidance test, and mood with the tail suspension test. Evaluations were conducted on the seventh- and twenty-eighth-day post DMCA occlusion to assess medium- and long-term effects of the injury, respectively. DMCA occlusion significantly decreases muscle strength and spontaneous locomotion (p < 0.05) both medium- and long term; as well as increases immobility in the tail-suspension test (p < 0.05), suggesting a depressive-type behavior. However, DMCA occlusion did not affect nociceptive threshold nor cognitive functions (p > 0.05). These results suggest that, medium- and long-term effects of DMCA occlusion include motor function impairments, but no sensory dysfunction. Additionally, the injury affected mood but did not hinder cognitive function.
Collapse
Affiliation(s)
- Juçara Loli de Oliveira
- Department of Morphological Sciences, Federal University of Santa Catarina, Santa Catarina, Brazil
| | - Marina Ávila
- Experimental Neuroscience Laboratory (LaNEx) and Postgraduate Program in Health Sciences, University of Southern Santa Catarina at Palhoça, 25 Pedra Branca Avenue, Santa Catarina, Brazil
| | - Thiago Cesar Martins
- Experimental Neuroscience Laboratory (LaNEx) and Postgraduate Program in Health Sciences, University of Southern Santa Catarina at Palhoça, 25 Pedra Branca Avenue, Santa Catarina, Brazil
| | - Marcio Alvarez-Silva
- Stem Cell and Bioengineering Laboratory, Department of Cell Biology, Embryology and Genetics, Federal University of Santa Catarina, Santa Catarina, Brazil
| | | | - Afonso Shiguemi Inoue Salgado
- Experimental Neuroscience Laboratory (LaNEx) and Postgraduate Program in Health Sciences, University of Southern Santa Catarina at Palhoça, 25 Pedra Branca Avenue, Santa Catarina, Brazil.,Postgraduate Program in Health Sciences, University of Southern Santa Catarina, Santa Catarina, Brazil.,Coordinator of Integrative Physical Therapy Residency, Philadelphia University Center, Londrina, PR Brazil
| | - Francisco José Cidral-Filho
- Experimental Neuroscience Laboratory (LaNEx) and Postgraduate Program in Health Sciences, University of Southern Santa Catarina at Palhoça, 25 Pedra Branca Avenue, Santa Catarina, Brazil.,Postgraduate Program in Health Sciences, University of Southern Santa Catarina, Santa Catarina, Brazil
| | - William R Reed
- Department of Physical Therapy, School of Health Professions, University of Alabama at Birmingham, Birmingham, AL USA
| | - Daniel F Martins
- Experimental Neuroscience Laboratory (LaNEx) and Postgraduate Program in Health Sciences, University of Southern Santa Catarina at Palhoça, 25 Pedra Branca Avenue, Santa Catarina, Brazil.,Postgraduate Program in Health Sciences, University of Southern Santa Catarina, Santa Catarina, Brazil
| |
Collapse
|
4
|
Fréchou M, Zhu X, Liere P, Pianos A, Schumacher M, Mattern C, Guennoun R. Dose-dependent and long-term cerebroprotective effects of intranasal delivery of progesterone after ischemic stroke in male mice. Neuropharmacology 2020; 170:108038. [PMID: 32151648 DOI: 10.1016/j.neuropharm.2020.108038] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Revised: 02/25/2020] [Accepted: 03/04/2020] [Indexed: 11/29/2022]
Abstract
Intranasal administration is emerging as a very promising route to deliver therapeutics to the brain. We have recently shown that the intranasal delivery of progesterone at 8 mg/kg is neuroprotective after stroke in male mice. To explore the translational potential of intranasal progesterone treatment, we performed a dose-response study and analyzed outcomes at 48 h after middle cerebral artery occlusion (MCAO). The effects on functional outcomes at long-term were examined by using the optimal dose. In the first experiment, male C57BL/6JRj mice were treated with progesterone at 8, 16 or 24 mg/kg, or with placebo at 1, 6 and 24 h post-MCAO. Our results show that the dose of 8 mg/kg was optimal in counteracting the early histopathological impairments as well as in improving functional recovery. Steroid profiling in plasma showed that the dose of 8 mg/kg is the one that leads to sustained high levels of progesterone and its neuroactive metabolites. In the second experiment, the dose of 8 mg/kg was used and analyzes were performed at 2, 7 and 21 days post-MCAO. Progesterone increased survival, glycemia and body weight. Furthermore, progesterone decreased neurological deficits and improved performances of mice on the rotarod and pole as early as 2 days and up to 21 days post-MCAO. These findings show that intranasal administration of progesterone has a significant translational potential as a cerebroprotective treatment after stroke that can be effective to reduce mortality, to limit tissue and cell damage at the acute phase; and to confer a long-term functional recovery.
Collapse
Affiliation(s)
- Magalie Fréchou
- U1195 Inserm and University Paris-Sud and University Paris-Saclay, 80 rue du Général Leclerc, 94276 Kremlin-Bicêtre, France.
| | - Xiaoyan Zhu
- U1195 Inserm and University Paris-Sud and University Paris-Saclay, 80 rue du Général Leclerc, 94276 Kremlin-Bicêtre, France.
| | - Philippe Liere
- U1195 Inserm and University Paris-Sud and University Paris-Saclay, 80 rue du Général Leclerc, 94276 Kremlin-Bicêtre, France.
| | - Antoine Pianos
- U1195 Inserm and University Paris-Sud and University Paris-Saclay, 80 rue du Général Leclerc, 94276 Kremlin-Bicêtre, France.
| | - Michael Schumacher
- U1195 Inserm and University Paris-Sud and University Paris-Saclay, 80 rue du Général Leclerc, 94276 Kremlin-Bicêtre, France.
| | - Claudia Mattern
- M et P Pharma AG, Schynweg 7, P.O.Box 138, 6376, Emmetten, Switzerland.
| | - Rachida Guennoun
- U1195 Inserm and University Paris-Sud and University Paris-Saclay, 80 rue du Général Leclerc, 94276 Kremlin-Bicêtre, France.
| |
Collapse
|
5
|
Wang X, Chang Y, He Y, Lyu C, Li H, Zhu J, Liu K, Hu Y, Huang K, Pan S. Glimepiride and glibenclamide have comparable efficacy in treating acute ischemic stroke in mice. Neuropharmacology 2019; 162:107845. [PMID: 31704276 DOI: 10.1016/j.neuropharm.2019.107845] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2019] [Revised: 10/27/2019] [Accepted: 11/04/2019] [Indexed: 12/20/2022]
Abstract
Glibenclamide protects against ischemic injury in both preclinical and clinical studies, presumably by blocking the de novo assembled sulfonylurea receptor 1-transient receptor potential M4 (Sur1-Trpm4) channel induced by ischemia. However, glibenclamide may cause unexpected serious hypoglycemia. Here, we tested whether glimepiride, another sulfonylurea with better safety, has comparable efficacy with glibenclamide and whether gene deletion of Trpm4 (Trpm4-/-) exerts similar effect. Wild-type (WT) mice subjected to temporary middle cerebral artery occlusion (tMCAO) were randomized to receive glibenclamide (an initial dose of 10 μg/kg and additional doses of 1.2 μg every 8 h), three different doses of glimepiride (10 μg/kg, 100 μg/kg and 1 mg/kg) or vehicle after ischemia, while tMCAO-treated Trpm4-/- mice were randomized to receive vehicle or glimepiride. Neurological function, infarct volume, edema formation, the integrity of blood-brain barrier and inflammatory reaction were evaluated at 24 h after ischemia. In tMCAO-treated WT mice, 10 μg/kg and 100 μg/kg glimepiride had comparable efficacy with glibenclamide in improving longa score and grip test score, reducing infarct volume, mitigating brain edema, lessening extravasation of Evans blue dye and IgG, restoring tight junction protein expression as well as suppressing inflammatory cytokines. Compared with WT mice, Trpm4-/- mice showed less neurological deficit, smaller cerebral infarction, lighter brain edema and more integrity of blood-brain barrier. As expected, glimepiride did not provide additional neuroprotection compared with vehicle in the tMCAO-treated Trpm4-/- mice. Glimepiride shows comparable efficacy with glibenclamide in alleviating brain injury after ischemic stroke in mice, possibly via targeting the Sur1-Trpm4 channel.
Collapse
Affiliation(s)
- Xiaoqiang Wang
- Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Yuan Chang
- Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Yihua He
- Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Chenfei Lyu
- Interdisciplinary Institute of Neuroscience and Technology, Zhejiang University School of Medicine, Hangzhou, China
| | - Hua Li
- Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Juan Zhu
- Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Kewei Liu
- Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Yafang Hu
- Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Kaibin Huang
- Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
| | - Suyue Pan
- Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
| |
Collapse
|
6
|
Klingbeil KD, Koch S, Dave KR. Potential link between post-acute ischemic stroke exposure to hypoglycemia and hemorrhagic transformation. Int J Stroke 2017; 15:477-483. [PMID: 29134928 DOI: 10.1177/1747493017743797] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Hemorrhagic transformation is a severe complication of acute ischemic stroke owing to its limited treatment options and poor prognosis. In the last decade, the rates of hemorrhagic transformation incidence have been associated with blood glucose levels. In particular, hyperglycemia at the time of admission has been associated with increased rates of hemorrhagic transformation in acute ischemic stroke patients. Recent pilot clinical trials have attempted to use intensive insulin therapy during stroke treatment to reduce the severity of cerebral infarction and possibly alleviate the risk of hemorrhagic transformation. However, the results of these studies have shown no clear clinical benefit. In addition, intensive insulin therapy has increased rates of hypoglycemia which may be associated with larger infarct growth. We hypothesize that hypoglycemia, similarly to hyperglycemia, is a risk factor for worse outcomes in acute ischemic stroke by promoting hemorrhagic transformation. This review serves to call attention to patterns present within intensive insulin therapy trials and shed light into the pathophysiological effects of hypoglycemia. It is critical that efforts be directed toward the prevention of hemorrhagic transformation by optimizing insulin therapy during the treatment of acute ischemic stroke.
Collapse
Affiliation(s)
- Kyle D Klingbeil
- Cerebral Vascular Disease Research Laboratories, Miller 12235 School of Medicine, University of Miami , Miami, FL, USA.,Department of Neurology, Miller 12235 School of Medicine, University of Miami , Miami, FL, USA
| | - Sebastian Koch
- Department of Neurology, Miller 12235 School of Medicine, University of Miami , Miami, FL, USA
| | - Kunjan R Dave
- Cerebral Vascular Disease Research Laboratories, Miller 12235 School of Medicine, University of Miami , Miami, FL, USA.,Department of Neurology, Miller 12235 School of Medicine, University of Miami , Miami, FL, USA.,Neuroscience Program, Miller 12235 School of Medicine, University of Miami , Miami, FL, USA
| |
Collapse
|
7
|
Zhu Z, Yang J, Zhong C, Xu T, Wang A, Bu X, Peng Y, Peng H, Xu T, Chen CS, Sun Y, Chen J, Zhang Y, He J. Abnormal glucose regulation, hypoglycemic treatment during hospitalization and prognosis of acute ischemic stroke. J Neurol Sci 2017; 379:177-182. [DOI: 10.1016/j.jns.2017.06.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Revised: 05/13/2017] [Accepted: 06/12/2017] [Indexed: 01/04/2023]
|
8
|
Abstract
Objective: To analyze the mechanism of neuroprotection of insulin and which blood glucose range was benefit for insulin exerting neuroprotective action. Data Sources: The study is based on the data from PubMed. Study Selection: Articles were selected with the search terms “insulin”, “blood glucose”, “neuroprotection”, “brain”, “glycogen”, “cerebral ischemia”, “neuronal necrosis”, “glutamate”, “γ-aminobutyric acid”. Results: Insulin has neuroprotection. The mechanisms include the regulation of neurotransmitter, promoting glycogen synthesis, and inhibition of neuronal necrosis and apoptosis. Insulin could play its role in neuroprotection by avoiding hypoglycemia and hyperglycemia. Conclusions: Intermittent and long-term infusion insulin may be a benefit for patients with ischemic brain damage at blood glucose 6–9 mmol/L.
Collapse
Affiliation(s)
| | - Yu Pei
- Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China
| |
Collapse
|
9
|
Saqqur M, Shuaib A, Alexandrov AV, Sebastian J, Khan K, Uchino K. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study. Int J Stroke 2015; 10:1087-92. [PMID: 26332252 DOI: 10.1111/ijs.12517] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Accepted: 02/25/2015] [Indexed: 01/04/2023]
Abstract
BACKGROUND The relationship between hyperglycemia and arterial recanalization following intravenous recombinant tissue-plasminogen activator treatment in acute ischemic stroke is not well understood. AIM We aimed to evaluate the effects of hyperglycemia in thrombolysed ischemic stroke patients on recanalization rate and clinical outcome. METHODS We studied 348 (231 subjects from the CLOTBUST databank and 117 subjects from the CLOTBUST trial phase II) with documented intracranial artery occlusion treated with intravenous recombinant tissue-plasminogen activator. Serum glucose was determined at baseline before intravenous recombinant tissue-plasminogen activator administration. Hyperglycemia was defined as a glucose level ≥140 mg/dl (7·7 mmol/l). Transcranial Doppler findings were interpreted using the thrombolysis in brain ischemia flow grading system as persistent arterial occlusion, re-occlusion or complete recanalization. Poor clinical outcome was defined by modified Rankin score > 2 at three-months. RESULTS At baseline, 138 patients (37·4%) were hyperglycemic and 210 patients (56·9%) normoglycemic. Baseline characteristics based on glucose ≥ 140 (7·7 mmol/l) or less 140: age (70·0 ± 12·4 vs. 67·3 ± 14·1, P = 0·065), baseline National Institutes of Health Stroke Scale (17·0 ± 5·5 vs. 15·8 ± 5·5, P = 0·054), time to recombinant tissue-plasminogen activator (141·4 ± 69·1 vs. 145·3 ± 48·4 mins, P = 0·56), and history of diabetes mellitus [60/138 (43·5%) vs. 22/210 (10·5%), P < 0·001]). Patients with hyperglycemia have a higher rate of persisting occlusion [72/138 (52·2%) vs. 66/210 (31·4%)] and less rate of complete recanalization [34/138 (24·6%) vs. 82/210 (39%), P < 0·001]. Median time to recanalization in patients with severe hyperglycemia (glucose ≥ 200) (11 mmol/l) and glucose <200 was 163 ± 79 and 131 ± 90 mins, respectively (P = 0·045). Sixteen patients (11·6%) in the hyperglycemic group and 12 (5·7%) in the normoglycemic group had symptomatic intracerebral hemorrhage (P = 0·049). Seventy-eight patients (69%) in the hyperglycemia group and 72 patients (41·6%) in the normoglycemic group had poor clinical outcome (three-month modified Rankin score > 2) (P ≤ 0·001). After adjusting for stroke risk factors, patients with hyperglycemia were more likely to have poor clinical outcome (three-month modified Rankin score > 2) (adjusted odds ratio = 2·22, 95% confidence interval: 1·2-4·11, P = 0·011) and low complete recanalization rate (adjusted odds ratio: 0·5, confidence interval: 0·3-0·92, P = 0·025) with trend of increase risk of symptomatic intracerebral hemorrhage (adjusted odds ratio: 2·07, confidence interval:0·8-5·1, P = 0·114). There was no association between baseline glucose as a continuous variable and poor clinical outcome, but there was with the complete recanalization's rate. CONCLUSION Hyperglycemia is associated with low rate of complete recanalization and poor clinical outcome in intravenous recombinant tissue-plasminogen activator-treated patients. Further studies are needed to evaluate whether lowering hyperglycemia is beneficial in the management of acute stroke patients.
Collapse
Affiliation(s)
- Maher Saqqur
- Department of Medicine (Neurology), University of Alberta, Edmonton, AB, Canada
| | - Ashfaq Shuaib
- Department of Medicine (Neurology), University of Alberta, Edmonton, AB, Canada
| | - Andrei V Alexandrov
- Department of Neurology and Semmes-Murphey, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Joseph Sebastian
- Department of Medicine (Neurology), University of Alberta, Edmonton, AB, Canada
| | - Khurshid Khan
- Department of Medicine (Neurology), University of Alberta, Edmonton, AB, Canada
| | - Ken Uchino
- Cerebrovascular Center, Cleveland Clinic Main Campus, Cleveland, OH, USA
| |
Collapse
|
10
|
Amaro S, Llull L, Renú A, Laredo C, Perez B, Vila E, Torres F, Planas AM, Chamorro Á. Uric acid improves glucose-driven oxidative stress in human ischemic stroke. Ann Neurol 2015; 77:775-83. [PMID: 25627874 DOI: 10.1002/ana.24378] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2014] [Revised: 01/24/2015] [Accepted: 01/25/2015] [Indexed: 01/04/2023]
Abstract
OBJECTIVE A study was undertaken to test in a subgroup reanalysis of the URICO-ICTUS trial whether uric acid is superior to placebo in improving the functional outcome in patients with acute stroke and hyperglycemia. METHODS Patients were part of the URICO-ICTUS trial, a double-blind study that compared the administration of uric acid versus placebo in stroke patients treated with alteplase within 4.5 hours of onset. The effect of therapy on the rate of excellent outcome at 90 days (modified Rankin Scale ≤ 2) in each tertile of admission glucose was assessed with multivariate adjusted models in 409 of the 421 randomized patients who had available pretreatment glucose levels. The effect of therapy on infarct growth was assessed in 72 patients who had longitudinal multimodal brain imaging. RESULTS Uric acid was associated with an increased rate of excellent outcome in patients with glucose levels in the upper tertile range (odds ratio [OR] = 2.9, 95% confidence interval [CI] = 1.0-8.3). However, the effect was not apparent for patients in the middle tertile (OR = 1.6, 95% CI = 0.8-3.6) or lower tertile of glucose (OR = 1.1, 95% CI = 0.5-2.6). Uric acid therapy was more effective than placebo in limiting infarct growth in the upper tertile range (Mann-Whitney U test, p = 0.04) but not in the middle tertile (p = 0.95) or lower tertile of glucose (p = 0.30). Uric acid also proved superior to placebo in reducing infarct growth in patients with early recanalization. INTERPRETATION Uric acid therapy was associated with reduced infarct growth and improved outcome in patients with hyperglycemia during acute stroke.
Collapse
Affiliation(s)
- Sergio Amaro
- Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona and August Pi i Sunyer Biomedical Research Institute, Barcelona
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Ntaios G, Papavasileiou V, Michel P, Tatlisumak T, Strbian D. Predicting functional outcome and symptomatic intracranial hemorrhage in patients with acute ischemic stroke: a glimpse into the crystal ball? Stroke 2015; 46:899-908. [PMID: 25657189 DOI: 10.1161/strokeaha.114.003665] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- George Ntaios
- From the Department of Medicine, University of Thessaly, Larissa, Greece (G.N., V.P.); Neurology Service, University of Lausanne, Lausanne, Switzerland (P.M.); and Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland (T.T., D.S.)
| | - Vasileios Papavasileiou
- From the Department of Medicine, University of Thessaly, Larissa, Greece (G.N., V.P.); Neurology Service, University of Lausanne, Lausanne, Switzerland (P.M.); and Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland (T.T., D.S.)
| | - Patrik Michel
- From the Department of Medicine, University of Thessaly, Larissa, Greece (G.N., V.P.); Neurology Service, University of Lausanne, Lausanne, Switzerland (P.M.); and Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland (T.T., D.S.)
| | - Turgut Tatlisumak
- From the Department of Medicine, University of Thessaly, Larissa, Greece (G.N., V.P.); Neurology Service, University of Lausanne, Lausanne, Switzerland (P.M.); and Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland (T.T., D.S.)
| | - Daniel Strbian
- From the Department of Medicine, University of Thessaly, Larissa, Greece (G.N., V.P.); Neurology Service, University of Lausanne, Lausanne, Switzerland (P.M.); and Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland (T.T., D.S.).
| |
Collapse
|
12
|
Seners P, Turc G, Oppenheim C, Baron JC. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry 2015; 86:87-94. [PMID: 24970907 DOI: 10.1136/jnnp-2014-308327] [Citation(s) in RCA: 171] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Early neurological deterioration (END) following ischaemic stroke is a serious event with manageable causes in only a fraction of patients. The incidence, causes and predictors of END occurring within 24 h of acute ischaemic stroke (END24) have not been systematically reviewed. We systematically reviewed Medline and Embase from January 1990 to April 2013 for all studies on END24 following acute ischaemic stroke (<8 h from onset). We recorded the incidence and presumed causes of and factors associated with END24. Thirty-six studies were included. Depending on the definition used, the incidence of END24 markedly varied among studies. Using the most widely used change in National Institutes of Health Stroke Scale ≥4 definition, the pooled incidence was 13.8% following thrombolysis, ascribed to intracranial haemorrhage and malignant oedema each in ∼20% of these. As other mechanisms were rarely reported, in the majority no clear cause was identified. Few data on END24 occurring in non-thrombolysed patients were available. Across thrombolysed and non-thrombolysed samples, the strongest and most consistent admission predictors were hyperglycaemia, no prior aspirin use, prior transient ischaemic attacks, proximal arterial occlusion and presence of early CT changes, and the most consistent 24 h follow-up associated factors were no recanalisation/reocclusion, large infarcts and intracranial haemorrhage. Finally, END24 was strongly predictive of poor outcome. The above findings are discussed with emphasis on END without a clear mechanism. Data on incidence and predictors of the latter subtype is scarce, and future studies using systematic imaging protocols should address its underlying pathophysiology. This may in turn lead to rational preventative and therapeutic measures for this ominous event.
Collapse
Affiliation(s)
- Pierre Seners
- Sorbonne Paris Cité, INSERM UMR S894, Service de Neurologie, Université Paris Descartes, Hôpital Sainte-Anne, Paris, France
| | - Guillaume Turc
- Sorbonne Paris Cité, INSERM UMR S894, Service de Neurologie, Université Paris Descartes, Hôpital Sainte-Anne, Paris, France
| | - Catherine Oppenheim
- Sorbonne Paris Cité, INSERM UMR S894, Service de Neuroradiologie, Centre Hospitalier Sainte-Anne, Université Paris Descartes, Paris, France
| | - Jean-Claude Baron
- Sorbonne Paris Cité, INSERM UMR S894, Service de Neurologie, Université Paris Descartes, Hôpital Sainte-Anne, Paris, France
| |
Collapse
|
13
|
Hyperglycemia, acute ischemic stroke, and thrombolytic therapy. Transl Stroke Res 2014; 5:442-453. [PMID: 24619488 DOI: 10.1007/s12975-014-0336-z] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Revised: 02/25/2014] [Accepted: 02/27/2014] [Indexed: 01/04/2023]
Abstract
Ischemic stroke is a leading cause of disability and is considered now the fourth leading cause of death. Many clinical trials have shown that stroke patients with acute elevation in blood glucose at onset of stroke suffer worse functional outcomes, longer in-hospital stay, and higher mortality rates. The only therapeutic hope for these patients is the rapid restoration of blood flow to the ischemic tissue through intravenous administration of the only currently proven effective therapy, tissue plasminogen activator (tPA). However, even this option is associated with the increased risk of intracerebral hemorrhage. Nonetheless, the underlying mechanisms through which hyperglycemia (HG) and tPA worsen the neurovascular injury after stroke are not fully understood. Accordingly, this review summarizes the latest updates and recommendations about the management of HG and coadministration of tPA in a clinical setting while focusing more on the various experimental models studying (1) the effect of HG on stroke outcomes, (2) the potential mechanisms involved in worsening the neurovascular injury, (3) the different therapeutic strategies employed to ameliorate the injury, and finally, (4) the interaction between HG and tPA. Developing therapeutic strategies to reduce the hemorrhage risk with tPA in hyperglycemic setting is of great clinical importance. This can best be achieved by conducting robust preclinical studies evaluating the interaction between tPA and other therapeutics in order to develop potential therapeutic strategies with high translational impact.
Collapse
|
14
|
Abstract
Evidence that acute injury and critical illness can result in an elevation of blood glucose levels is not a new concept. However, the last decade has seen a rise in publications describing the potential harm of this unique form of hyperglycemia and the subsequent benefits of glucose control. More recently, the untoward effects of tightly controlling glucose concentrations in this setting have been more thoroughly elucidated. This has lead to a challenging clinical conundrum for practitioners both inside and outside of the intensive care unit. The latest guidelines attempt to shed light on this dilemma and provide guidance for practitioners. This article reviews the progression of the research, the multiple guidelines that have been published, and the clinical implications on the treatment of critical illness hyperglycemia, with particular focus on the emergency department.
Collapse
|
15
|
Bruno A, Durkalski VL, Hall CE, Juneja R, Barsan WG, Janis S, Meurer WJ, Fansler A, Johnston KC. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. Int J Stroke 2013; 9:246-51. [PMID: 23506245 DOI: 10.1111/ijs.12045] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
RATIONALE Patients with acute ischemic stroke and hyperglycemia have worse outcomes than those without hyperglycemia. Intensive glucose control during acute stroke is feasible and can be accomplished safely but has not been fully assessed for efficacy. AIMS The Stroke Hyperglycemia Insulin Network Effort trial aims to determine the safety and efficacy of standard vs. intensive glucose control with insulin in hyperglycemic acute ischemic stroke patients. DESIGN This is a randomized, blinded, multicenter, phase III trial of approximately 1400 hyperglycemic patients who receive either standard sliding scale subcutaneous insulin (blood glucose range 80-179 mg/dL, 4·44-9·93 mmol/L) or continuous intravenous insulin (target blood glucose 80-130 mg/dL, 4·44-7·21 mmol/L) for up to 72 h, starting within 12 h of stroke symptom onset. The acute treatment phase is single blind (for the patients), but the final outcome assessment is double blind. The study is powered to detect a 7% absolute difference in favorable outcome at 90 days. STUDY OUTCOMES The primary outcome is a baseline severity adjusted 90-day modified Rankin Scale score, defined as 0, 0-1, or 0-2, if the baseline National Institutes of Health Stroke Scale score is 3-7, 8-14, or 15-22, respectively. The primary safety outcome is the rate of severe hypoglycemia (<40 mg/dL, <2·22 mmol/L). DISCUSSION This trial will provide important novel information about preferred management of acute ischemic stroke patients with hyperglycemia. It will determine the potential benefits and risks of intensive glucose control during acute stroke.
Collapse
Affiliation(s)
- Askiel Bruno
- Department of Neurology, Medical College of Georgia, Augusta, GA, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Wang YY, Chen CJ, Lin SY, Chuang YH, Sheu WHH, Tung KC. Hyperglycemia is associated with enhanced gluconeogenesis in a rat model of permanent cerebral ischemia. Mol Cell Endocrinol 2013; 367:50-6. [PMID: 23279876 DOI: 10.1016/j.mce.2012.12.016] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2012] [Revised: 12/17/2012] [Accepted: 12/18/2012] [Indexed: 12/25/2022]
Abstract
Hyperglycemia is common after acute stroke. In the acute phase of stroke (within 24h), rats with permanent cerebral ischemia developed higher fasting blood glucose and insulin levels in association with up-regulation of hepatic gluconeogenic gene expression, including phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, and fructose-1,6-bisphosphatase. In addition, hepatic gluconeogenesis-associated positive regulators, such as FoxO1, CAATT/enhancer-binding proteins (C/EBPs), and cAMP responsive element-binding protein (CREB), were up-regulated. For insulin signaling transduction, phosphorylation of insulin receptor (IR), insulin receptor substrate-1 (IRS1) at the tyrosine residue, Akt, and AMP-activated protein kinase (AMPK), were attenuated in the liver, while negative regulators of insulin action, including phosphorylation of p38, c-Jun N-terminal kinase (JNK), and insulin receptor substrate-1 (IRS1) at the serine residue, were increased. In addition, the brains of rats with stroke exhibited a reduction in phosphorylation of IRS1 at the tyrosine residue and Akt. Circulating cortisol, glucagon, C-reactive protein (CRP), monocyte chemoattractant protein 1 (MCP-1), and resistin levels were elevated, but adiponectin was reduced. Our data suggest that cerebral ischemic insults might modify intracellular and extracellular environments, favoring hepatic gluconeogenesis and the consequences of hyperglycemia.
Collapse
Affiliation(s)
- Ya-Yu Wang
- Division of Family Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
| | | | | | | | | | | |
Collapse
|
17
|
Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med 2013; 40:3251-76. [PMID: 23164767 DOI: 10.1097/ccm.0b013e3182653269] [Citation(s) in RCA: 372] [Impact Index Per Article: 33.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVE To evaluate the literature and identify important aspects of insulin therapy that facilitate safe and effective infusion therapy for a defined glycemic end point. METHODS Where available, the literature was evaluated using Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) methodology to assess the impact of insulin infusions on outcome for general intensive care unit patients and those in specific subsets of neurologic injury, traumatic injury, and cardiovascular surgery. Elements that contribute to safe and effective insulin infusion therapy were determined through literature review and expert opinion. The majority of the literature supporting the use of insulin infusion therapy for critically ill patients lacks adequate strength to support more than weak recommendations, termed suggestions, such that the difference between desirable and undesirable effect of a given intervention is not always clear. RECOMMENDATIONS The article is focused on a suggested glycemic control end point such that a blood glucose ≥ 150 mg/dL triggers interventions to maintain blood glucose below that level and absolutely <180 mg/dL. There is a slight reduction in mortality with this treatment end point for general intensive care unit patients and reductions in morbidity for perioperative patients, postoperative cardiac surgery patients, post-traumatic injury patients, and neurologic injury patients. We suggest that the insulin regimen and monitoring system be designed to avoid and detect hypoglycemia (blood glucose ≤ 70 mg/dL) and to minimize glycemic variability.Important processes of care for insulin therapy include use of a reliable insulin infusion protocol, frequent blood glucose monitoring, and avoidance of finger-stick glucose testing through the use of arterial or venous glucose samples. The essential components of an insulin infusion system include use of a validated insulin titration program, availability of appropriate staffing resources, accurate monitoring technology, and standardized approaches to infusion preparation, provision of consistent carbohydrate calories and nutritional support, and dextrose replacement for hypoglycemia prevention and treatment. Quality improvement of glycemic management programs should include analysis of hypoglycemia rates, run charts of glucose values <150 and 180 mg/dL. The literature is inadequate to support recommendations regarding glycemic control in pediatric patients. CONCLUSIONS While the benefits of tight glycemic control have not been definitive, there are patients who will receive insulin infusion therapy, and the suggestions in this article provide the structure for safe and effective use of this therapy.
Collapse
|
18
|
Dunn JF, Wu Y, Zhao Z, Srinivasan S, Natah SS. Training the brain to survive stroke. PLoS One 2012; 7:e45108. [PMID: 23028788 PMCID: PMC3441606 DOI: 10.1371/journal.pone.0045108] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2012] [Accepted: 08/14/2012] [Indexed: 12/20/2022] Open
Abstract
Background Presently, little can be done to repair brain tissue after stroke damage. We hypothesized that the mammalian brain has an intrinsic capacity to adapt to low oxygen which would improve outcome from a reversible hypoxic/ischemic episode. Acclimation to chronic hypoxia causes increased capillarity and tissue oxygen levels which may improve the capacity to survive ischemia. Identification of these adaptations will lead to protocols which high risk groups could use to improve recovery and reduce costs. Methods and Findings Rats were exposed to hypoxia (3 weeks living at ½ an atmosphere). After acclimation, capillary density was measured morphometrically and was increased by 30% in the cortex. Novel implantable oxygen sensors showed that partial pressure of oxygen in the brain was increased by 40% in the normal cortex. Infarcts were induced in brain with 1 h reversible middle cerebral artery occlusions. After ischemia (48 h) behavioural scores were improved and T2 weighted MRI lesion volumes were reduced by 52% in acclimated groups. There was a reduction in inflammation indicated by reduced lymphocytes (by 27–33%), and ED1 positive cells (by 35–45%). Conclusions It is possible to stimulate a natural adaptive mechanism in the brain which will reduce damage and improve outcome for a given ischemic event. Since these adaptations occur after factors such as HIF-1α have returned to baseline, protection is likely related more to morphological changes such as angiogenesis. Such pre-conditioning, perhaps with exercise or pharmaceuticals, would not necessarily reduce the incidence of stroke, but the severity of damage could be reduced by 50%.
Collapse
Affiliation(s)
- Jeff F Dunn
- Department of Radiology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
| | | | | | | | | |
Collapse
|
19
|
Rosso C, Corvol JC, Pires C, Crozier S, Attal Y, Jacqueminet S, Deltour S, Multlu G, Leger A, Meresse I, Payan C, Dormont D, Samson Y. Intensive Versus Subcutaneous Insulin in Patients With Hyperacute Stroke. Stroke 2012; 43:2343-9. [DOI: 10.1161/strokeaha.112.657122] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Background and Purpose—
Intensive insulin therapy (IIT) has not yet proven its efficacy on stroke prognosis or in the reduction of MRI infarct growth. The INSULINFARCT study aims at determining in patients with hyperacute stroke whether IIT, with a better control of poststroke hyperglycemia, would reduce subsequent MRI infarct growth than usual care with subcutaneous insulin.
Methods—
One hundred eighty patients with MRI-proven ischemic stroke and with National Institutes of Health Stroke Scale from 5 to 25 at admission (<6 hours) were randomized to receive IIT or usual subcutaneous insulin for 24 hours. Admission hyperglycemia was not required for recruitment. Control MRI and 3-month follow-up (with functional outcome and serious adverse events) were planned. The primary objective was to detect a difference in the proportion of patients with mean capillary glucose test <7 mmol/L during 24 hours. The secondary objective was to investigate whether IIT would reduce infarct growth. The analysis was planned in intention-to-treat. Patients with >3 missing capillary glucose test were excluded (n=4).
Results—
The proportion of patients with mean capillary glucose test <7 mmol/L in the first 24 hours was higher in the IIT group (95.4% [83 of 87] versus 67.4% [60 of 89];
P
<0.0001). The infarct growth was lower in the subcutaneous insulin group (median, 10.8 cm
3
; 95% CI, 6.5–22.4 versus 27.9 cm
3
; 14.6–40.7; 60% of increase;
P
=0.04). The 3-month functional outcome (45.6% [41 of 90] versus 45.6% [41 of 90]), death (15.6% [14 of 90] versus 10% [9 of 90]), and serious adverse events (38.9% [35 of 90] versus 35.6% [32 of 90]) were similar in the subcutaneous insulin and IIT group.
Conclusion—
The IIT regimen improved glucose control in the first 24 hours of stroke but was associated with larger infarct growths. IIT cannot be recommended in hyperacute ischemic stroke.
Clinical Trial Registration—
URL:
http://clinicaltrials.gov
. Unique Identifier: NCT00472381.
Collapse
Affiliation(s)
- Charlotte Rosso
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Jean-Christophe Corvol
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Christine Pires
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Sophie Crozier
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Yohan Attal
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Sophie Jacqueminet
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Sandrine Deltour
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Gurkan Multlu
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Anne Leger
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Isabelle Meresse
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Christine Payan
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Didier Dormont
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| | - Yves Samson
- From the AP-HP, Urgences Cérébro-Vasculaires, Pitié-Salpêtrière Hospital, Paris, France (C.R., C. Pires, S.C., S.D., G.M., A.L., I.M., Y.S.); UPMC, Univ Paris 06, Paris, France (C.R., J.-C.C., Y.A., D.D., Y.S.); COGIMAGE, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR 7225, Paris, France (C.R., Y.A., D.D., Y.S.); AP-HP, Service de Neurologie Pharmacologie Clinique, Pitié-Salpêtrière Hospital, Paris, France (J.-C.C., C. Payan); Centre
| |
Collapse
|
20
|
Schauwecker PE. The effects of glycemic control on seizures and seizure-induced excitotoxic cell death. BMC Neurosci 2012; 13:94. [PMID: 22867059 PMCID: PMC3465215 DOI: 10.1186/1471-2202-13-94] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2012] [Accepted: 07/24/2012] [Indexed: 12/20/2022] Open
Abstract
Background Epilepsy is the most common neurological disorder after stroke, affecting more than 50 million persons worldwide. Metabolic disturbances are often associated with epileptic seizures, but the pathogenesis of this relationship is poorly understood. It is known that seizures result in altered glucose metabolism, the reduction of intracellular energy metabolites such as ATP, ADP and phosphocreatine and the accumulation of metabolic intermediates, such as lactate and adenosine. In particular, it has been suggested that the duration and extent of glucose dysregulation may be a predictor of the pathological outcome of status. However, little is known about neither the effects of glycemic control on brain metabolism nor the effects of managing systemic glucose concentrations in epilepsy. Results In this study, we examined glycemic modulation of kainate-induced seizure sensitivity and its neuropathological consequences. To investigate the relationship between glycemic modulation, seizure susceptibility and its neuropathological consequences, C57BL/6 mice (excitotoxin cell death resistant) were subjected to hypoglycemia or hyperglycemia, followed by systemic administration of kainic acid to induce seizures. Glycemic modulation resulted in minimal consequences with regard to seizure severity but increased hippocampal pathology, irrespective of whether mice were hypoglycemic or hyperglycemic prior to kainate administration. Moreover, we found that exogenous administration of glucose following kainic acid seizures significantly reduced the extent of hippocampal pathology in FVB/N mice (excitotoxin cell death susceptible) following systemic administration of kainic acid. Conclusion These findings demonstrate that modulation of the glycemic index can modify the outcome of brain injury in the kainate model of seizure induction. Moreover, modulation of the glycemic index through glucose rescue greatly diminishes the extent of seizure-induced cell death following kainate administration. Our data support the hypothesis that deficient insulin signaling may represent a critical contributing factor in the susceptibility to seizure-induced cell death and this may be an important therapeutic target.
Collapse
Affiliation(s)
- Paula Elyse Schauwecker
- Department of Cell and Neurobiology, USC Keck School of Medicine, 1333 San Pablo Street, BMT 403, Los Angeles, CA 90089-9112, USA.
| |
Collapse
|
21
|
Affiliation(s)
- Katja Piironen
- From the Department of Neurology (K.P., J.P.), Helsinki University Central Hospital, Helsinki, Finland; APHP the Cerebrovascular Emergency Department (C.R., Y.S.), Groupe Hospitalier Pitié-Salpêtrière and Paris VI université, Paris, France; and Unité mixte de recherche_UMR 7225 (C.R., Y.S.), COGIMAGE, Centre de recherche de l'institut du cerveau et de la moelle épinière, Paris, France
| | - Jukka Putaala
- From the Department of Neurology (K.P., J.P.), Helsinki University Central Hospital, Helsinki, Finland; APHP the Cerebrovascular Emergency Department (C.R., Y.S.), Groupe Hospitalier Pitié-Salpêtrière and Paris VI université, Paris, France; and Unité mixte de recherche_UMR 7225 (C.R., Y.S.), COGIMAGE, Centre de recherche de l'institut du cerveau et de la moelle épinière, Paris, France
| | - Charlotte Rosso
- From the Department of Neurology (K.P., J.P.), Helsinki University Central Hospital, Helsinki, Finland; APHP the Cerebrovascular Emergency Department (C.R., Y.S.), Groupe Hospitalier Pitié-Salpêtrière and Paris VI université, Paris, France; and Unité mixte de recherche_UMR 7225 (C.R., Y.S.), COGIMAGE, Centre de recherche de l'institut du cerveau et de la moelle épinière, Paris, France
| | - Yves Samson
- From the Department of Neurology (K.P., J.P.), Helsinki University Central Hospital, Helsinki, Finland; APHP the Cerebrovascular Emergency Department (C.R., Y.S.), Groupe Hospitalier Pitié-Salpêtrière and Paris VI université, Paris, France; and Unité mixte de recherche_UMR 7225 (C.R., Y.S.), COGIMAGE, Centre de recherche de l'institut du cerveau et de la moelle épinière, Paris, France
| |
Collapse
|
22
|
Harada S, Fujita-Hamabe W, Tokuyama S. Ischemic Stroke and Glucose Intolerance: a Review of the Evidence and Exploration of Novel Therapeutic Targets. J Pharmacol Sci 2012; 118:1-13. [DOI: 10.1254/jphs.11r04cr] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2011] [Accepted: 09/21/2011] [Indexed: 10/14/2022] Open
|
23
|
Bruno A, Liebeskind D, Hao Q, Raychev R. Diabetes mellitus, acute hyperglycemia, and ischemic stroke. Curr Treat Options Neurol 2011; 12:492-503. [PMID: 20848328 PMCID: PMC2943579 DOI: 10.1007/s11940-010-0093-6] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Acute brain ischemia is a dynamic process susceptible to multiple modulating factors, such as blood glucose level. During acute ischemic brain injury, hyperglycemia exacerbates multiple deleterious derangements. Timely and sufficient correction of hyperglycemia during acute brain ischemia may limit the brain injury and improve clinical outcomes. The clinical efficacy of such intervention remains to be proven. Although results from animal and clinical observational studies suggest that hyperglycemia during acute brain ischemia may exacerbate the brain injury, there is no evidence from randomized treatment trials that rapid correction of the hyperglycemia improves outcomes. Given the excess effort, cost, and risk involved in rapid and safe correction of hyperglycemia during acute stroke, less aggressive treatments with subcutaneous insulin seem appropriate at this time. Subcutaneous insulin protocols can maintain blood glucose levels below 200 mg/dL a majority of the time in most patients, especially if basal insulin is added. When available, an endocrinology consultant can optimize the acute treatment and help the transition to long-term care. Given the multiple reports linking admission hyperglycemia with symptomatic hemorrhagic conversion of ischemic stroke treated with thrombolytic drugs, it may be best to rapidly lower severe hyperglycemia in such patients. For example, if the admission blood glucose is approximately 300 mg/dL and the patient is a candidate for thrombolytic therapy, consider giving an intravenous bolus of regular insulin 8 units. Somewhat lower or higher insulin doses may be best for lesser or greater hyperglycemia. Such a bolus will start lowering the blood glucose in about 5 min. A temporary continuous intravenous insulin infusion may then be used in most patients to maintain the glucose closer to normal levels (eg, below 180 or 140 mg/dL).
Collapse
Affiliation(s)
- Askiel Bruno
- Department of Neurology, Medical College of Georgia, 1120 15th Street, BI3076, Augusta, GA, 30912, USA,
| | | | | | | |
Collapse
|
24
|
Hyperglycaemia and infarct size in animal models of middle cerebral artery occlusion: systematic review and meta-analysis. J Cereb Blood Flow Metab 2011; 31:807-18. [PMID: 21157471 PMCID: PMC3063635 DOI: 10.1038/jcbfm.2010.210] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Poststroke hyperglycaemia (PSH) is common, has an unclear pathophysiology, and is associated with poor outcomes. Animal studies report conflicting findings. We systematically reviewed the effects of hyperglycaemia on infarct volume in middle cerebral artery occlusion (MCAO) models, generating weighted mean differences between groups using random effects models summarised as effect size (normalised to control group infarct volume as 100%) and 95% confidence interval. Of 72 relevant papers, 23 reported infarct volume. Studies involved 664 animals and 35 distinct comparisons. Hyperglycaemia was induced by either streptozotocin (STZ, 17 comparisons, n=303) or dextrose (18 comparisons, n=356). Hyperglycaemic animals had infarcts that were 94% larger, but STZ was associated with significantly greater increase in infarct volumes than dextrose infusion (140% larger versus 48% larger). In seven studies, insulin did not significantly reduce infarct size and results were heterogeneous. Although hyperglycaemia exacerbates infarct volume in MCAO models, studies are heterogeneous, and do not address the common clinical problem of PSH because they have used either the STZ model of type I diabetes or extremely high glucose loads. Insulin had a nonsignificant and significantly heterogeneous effect. Further studies with relevant models may inform clinical trial design.
Collapse
|
25
|
Natarajan SK, Dandona P, Karmon Y, Yoo AJ, Kalia JS, Hao Q, Hsu DP, Hopkins LN, Fiorella DJ, Bendok BR, Nguyen TN, Rymer MM, Nanda A, Liebeskind DS, Zaidat OO, Nogueira RG, Siddiqui AH, Levy EI. Prediction of adverse outcomes by blood glucose level after endovascular therapy for acute ischemic stroke. J Neurosurg 2011; 114:1785-99. [PMID: 21351835 DOI: 10.3171/2011.1.jns10884] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
OBJECT The authors evaluated the prognostic significance of blood glucose level at admission (BGA) and change in blood glucose at 48 hours from the baseline value (CG48) in nondiabetic and diabetic patients before and after endovascular therapy for acute ischemic stroke (AIS). METHODS The BGA and CG48 data were analyzed in 614 patients with AIS who received endovascular therapy at 7 US centers between 2006 and 2009. Data reviewed included demographics, stroke risk factors, diabetic status, National Institutes of Health Stroke Scale (NIHSS) score at presentation, recanalization grade, intracranial hemorrhage (ICH) rate, and 90-day outcomes (mortality rate and modified Rankin Scale score of 3-6 [defined as poor outcome]). Variables with p values < 0.2 in univariate analysis were included in a binary logistic regression model for independent predictors of 90-day outcomes. RESULTS The mean patient age was 67.3 years, the median NIHSS score was 16, and 27% of patients had diabetes. In nondiabetic patients, BGA ≥ 116 mg/dl (≥ 6.4 mmol/L) and failure of glucose level to drop > 30 mg/dl (> 1.7 mmol/L) from the admission value were both significant predictors of 90-day poor outcome and death (p < 0.001). In patients with diabetes, BGA ≥ 116 mg/dl (≥ 6.4 mmol/L) was an independent predictor of poor outcome (p = 0.001). The CG48 was not a predictor of outcome in diabetic patients. A simplified 6-point scale including BGA, Thrombolysis in Myocardial Infarction (TIMI) Grade 2-3 Reperfusion, Age, presentation NIHSS score, CG48, and symptomatic ICH (BRANCH) corresponded with poor outcomes at 90 days; the area under the curve value was > 0.79. CONCLUSIONS Failure of blood glucose values to decrease in the first 48 hours after AIS intervention correlated with poor 90-day outcomes in nondiabetic patients. The BRANCH scale shows promise as a simple prognostication tool after endovascular therapy for AIS, and it merits prospective validation.
Collapse
|
26
|
Mielke JG, Wang YT. Insulin, synaptic function, and opportunities for neuroprotection. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2011; 98:133-86. [PMID: 21199772 DOI: 10.1016/b978-0-12-385506-0.00004-1] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
A steadily growing number of studies have begun to establish that the brain and insulin, while traditionally viewed as separate, do indeed have a relationship. The uptake of pancreatic insulin, along with neuronal biosynthesis, provides neural tissue with the hormone. As well, insulin acts upon a neuronal receptor that, although a close reflection of its peripheral counterpart, is characterized by unique structural and functional properties. One distinction is that the neural variant plays only a limited part in neuronal glucose transport. However, a number of other roles for neural insulin are gradually emerging; most significant among these is the modulation of ligand-gated ion channel (LGIC) trafficking. Notably, insulin has been shown to affect the tone of synaptic transmission by regulating cell-surface expression of inhibitory and excitatory receptors. The manner in which insulin regulates receptor movement may provide a cellular mechanism for insulin-mediated neuroprotection in the absence of hypoglycemia and stimulate the exploration of new therapeutic opportunities.
Collapse
Affiliation(s)
- John G Mielke
- Faculty of Applied Health Sciences, Department of Health Studies and Gerontology, University of Waterloo, Waterloo, Ontario, Canada
| | | |
Collapse
|
27
|
Ntaios G, Egli M, Faouzi M, Michel P. J-Shaped Association Between Serum Glucose and Functional Outcome in Acute Ischemic Stroke. Stroke 2010; 41:2366-70. [DOI: 10.1161/strokeaha.110.592170] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- George Ntaios
- From Neurology Service (G.N., P.M.), Service of Endocrinology, Diabetes, and Metabolism (M.E.), and Institute of Social and Preventive Medicine (M.F.), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - Marc Egli
- From Neurology Service (G.N., P.M.), Service of Endocrinology, Diabetes, and Metabolism (M.E.), and Institute of Social and Preventive Medicine (M.F.), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - Mohamed Faouzi
- From Neurology Service (G.N., P.M.), Service of Endocrinology, Diabetes, and Metabolism (M.E.), and Institute of Social and Preventive Medicine (M.F.), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - Patrik Michel
- From Neurology Service (G.N., P.M.), Service of Endocrinology, Diabetes, and Metabolism (M.E.), and Institute of Social and Preventive Medicine (M.F.), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
28
|
Quinn TJ, Dawson J, Walters MR. Sugar and Stroke: Cerebrovascular Disease and Blood Glucose Control. Cardiovasc Ther 2010; 29:e31-42. [DOI: 10.1111/j.1755-5922.2010.00166.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
|
29
|
Abstract
Patients with acute ischemic stroke frequently test positive for hyperglycemia, which is associated with a poor clinical outcome. This association between poor glycemic control and an unfavorable prognosis is particularly evident in patients with persistent hyperglycemia, patients without a known history of diabetes mellitus, and patients with cortical infarction. To date, however, only one large clinical trial has specifically investigated the effect of glycemic control on stroke outcome. This trial failed to show a clinical benefit, but had several limitations. Despite a lack of clinical evidence supporting the use of glycemic control in the treatment of patients with stroke, international guidelines recommend treating this subset of critically ill patients for hyperglycemia in the hospital setting. This treatment regime is, however, particularly challenging in patients with stroke, and is associated with an increased risk of the patient developing hypoglycemia. Here we review the available evidence linking hyperglycemia to a poor clinical outcome in patients with ischemic stroke. We highlight the pathophysiological mechanisms that might underlie the deleterious effects of hyperglycemia on acute stroke prognosis and systematically review the literature concerning tight glycemic control after stroke. Finally, we provide directions on the use of insulin treatment strategies to control hyperglycemia in this patient group.
Collapse
|
30
|
Abstract
Diabetes is not only an independent risk factor for lacunar infarction, especially in patients with multiple lacunar infarcts, but the presence of diabetes is also associated with worse functional recovery in these patients.
Collapse
|
31
|
Kim N, Jhang Y, Park JM, Kim BK, Kwon O, Lee J, Lee JS, Koo JS. Aggressive glucose control for acute ischemic stroke patients by insulin infusion. J Clin Neurol 2009; 5:167-72. [PMID: 20076797 PMCID: PMC2806538 DOI: 10.3988/jcn.2009.5.4.167] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2009] [Revised: 09/28/2009] [Accepted: 09/28/2009] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND AND PURPOSE Hyperglycemia after acute ischemic stroke (AIS) is associated with poor outcomes. However, there is no consensus as to the optimal method for glycemic control. We designed an insulin infusion protocol for aggressive glucose control and investigated its efficacy and safety. METHODS We applied our protocol to patients within 48 hours after AIS or transient ischemic attack (TIA) with an initial capillary glucose level of between 100 and 399 mg/dL (5.6-22.2 mmol/L). An insulin solution comprising 40 or 50 U of human regular insulin in 500 mL of 5% dextrose was administered for 24 hours. Capillary glucose was measured every 2 hours and the infusion rate was adjusted according to a nomogram with a target range of 80-129 mg/dL (4.4-7.2 mmol/L). Changes in glucose and overall glucose levels during insulin infusion were analyzed according to the presence of diabetes or admission hyperglycemia (admission glucose >139 mg/dL or 7.7 mmol/L) by the generalized estimating equation method. RESULTS The study cohort comprised 115 consecutive patients. Glucose was significantly lowered from 160+/-57 mg/dL (8.9+/-3.2 mmol/L) at admission to 93+/-28 mg/dL (5.2+/-1.6 mmol/L) during insulin infusion (p<0.05). Laboratory hypoglycemia (capillary glucose <80 mg/dL or 4.4 mmol/L) occurred in 91 (71%) patients, 11 (10%) of whom had symptomatic hypoglycemia. Although glucose levels were significantly lowered and maintained within the target range in all patients, overall glucose levels were significantly higher in patients with diabetes or hyperglycemia (p<0.05). CONCLUSIONS Our insulin-infusion protocol was effective in glycemic control for patients with AIS or TIA. Further modification is needed to improve the efficacy and safety of this procedure, and tailored intervention should be considered according to glycemic status.
Collapse
Affiliation(s)
- Nayoung Kim
- Department of Neurology, Eulji General Hospital, Eulji University College of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Braeuninger S, Kleinschnitz C. Rodent models of focal cerebral ischemia: procedural pitfalls and translational problems. EXPERIMENTAL & TRANSLATIONAL STROKE MEDICINE 2009; 1:8. [PMID: 20150986 PMCID: PMC2820446 DOI: 10.1186/2040-7378-1-8] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/13/2009] [Accepted: 11/25/2009] [Indexed: 11/10/2022]
Abstract
Rodent models of focal cerebral ischemia are essential tools in experimental stroke research. They have added tremendously to our understanding of injury mechanisms in stroke and have helped to identify potential therapeutic targets. A plethora of substances, however, in particular an overwhelming number of putative neuroprotective agents, have been shown to be effective in preclinical stroke research, but have failed in clinical trials. A lot of factors may have contributed to this failure of translation from bench to bedside. Often, deficits in the quality of experimental stroke research seem to be involved. In this article, we review the commonest rodent models of focal cerebral ischemia - middle cerebral artery occlusion, photothrombosis, and embolic stroke models - with their respective advantages and problems, and we address the issue of quality in preclinical stroke modeling as well as potential reasons for translational failure.
Collapse
Affiliation(s)
- Stefan Braeuninger
- Department of Neurology, Julius-Maximilians-Universitaet Wuerzburg, Josef-Schneider-Str. 11, 97080 Wuerzburg, Germany.
| | | |
Collapse
|
33
|
Subjecting Acute Ischemic Stroke Patients to Continuous Tube Feeding and an Intensive Computerized Protocol Establishes Tight Glycemic Control. Neurocrit Care 2009; 12:62-8. [DOI: 10.1007/s12028-009-9230-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2009] [Accepted: 04/28/2009] [Indexed: 01/04/2023]
|
34
|
Harada S, Fujita WH, Shichi K, Tokuyama S. The development of glucose intolerance after focal cerebral ischemia participates in subsequent neuronal damage. Brain Res 2009; 1279:174-81. [PMID: 19445903 DOI: 10.1016/j.brainres.2009.05.014] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2009] [Revised: 04/30/2009] [Accepted: 05/02/2009] [Indexed: 11/29/2022]
Abstract
Hyperglycemia is a known exacerbating factor in ischemic stroke; however, most information is limited to pre-ischemic hyperglycemia, while little is known about post-ischemic hyperglycemia. In addition, it has been clinically reported that hyperglycemia can develop after stroke, but the detailed mechanisms underlying this are unknown. Here, we focused on the relationship between post-ischemic hyperglycemia and the development of neuronal damage. In particular, we investigated the time course of alterations in fasting blood glucose levels (FBG) and the development of neuronal damage, including neuronal death (the development of infarction), behavioral abnormality and memory disturbance, using middle cerebral artery occlusion (MCAO) model mice. The neuronal death was observed from 6 h, reaching a maximum on day 3 and was gradually aggravated up to day 5 after MCAO. Interestingly, 12 h and 1 day after MCAO, FBG was significantly increased and insulin sensitivity and insulin secretory capacity were decreased on 1 day after MCAO. In addition, we found that the basal plasma insulin levels were significantly higher and adiponectin levels were significantly lower on day 1 in the MCAO group compared with the sham group. These results indicate that the development of glucose intolerance was observed on day 1. Importantly, the neuronal damage observed on day 3 was completely suppressed by continuous administration of insulin during the first 48 h after MCAO. These results suggest that the post-ischemic hyperglycemia in the early phase of ischemic stress may be involved in the development of neuronal damage.
Collapse
Affiliation(s)
- Shinichi Harada
- Department of Clinical Pharmacy, Kobe Gakuin University, Faculty of Pharmaceutical Sciences, Chuo-ku, Kobe, Japan
| | | | | | | |
Collapse
|
35
|
Stress insulin resistance is a marker for mortality in traumatic brain injury. ACTA ACUST UNITED AC 2009; 66:145-51; discussion 151-3. [PMID: 19131817 DOI: 10.1097/ta.0b013e3181938c5e] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Both hyper- and hypoglycemia have been associated with poor outcome in traumatic brain injury (TBI). Neither the risks nor benefit of tight glucose control (goal range, 80-110 mg/dL) have been documented in the TBI population. OBJECTIVE To analyze whether densely collected blood glucose data, using a computerized algorithm, to maintain tight glycemic control will reveal significant differences in blood glucose control between survivors and nonsurvivors in patients with TBI. METHODS From October 2005 to April 2006, all ventilated, critically ill surgical patients with TBI Abbreviated Injury Scale score of >or=3 were placed on an automated, euglycemia protocol with every 2-hour blood glucose sampling. Mortalities within 24 hours were excluded. The protocol calculates the insulin rate using a linear equation (rate = blood glucose - 60[M]). M is an adapting multiplier and used here as a marker for insulin resistance (IR). RESULTS Of 1,636 trauma intensive care unit admissions 160 patients, (median Injury Severity Score 34, mortality 13.1%) had 10,071 samples collected. Median glucose 115.6 mg/dL, with 41% of values between 80 and 110 mg/dL, 81% between 80 and 150 mg/dL, and 0.3% <40 mg/dL. The median blood glucose was statistically different but not clinically different among the patients who lived and died (114; interquartile range, 109-132 vs. 118; 111-136, p = 0.01). The median insulin dose was a unit per hour higher among the patient who died (4.2; 2.7-5.9 vs. 3.2; 2.4-5.0, p = 0.006). A logistic regression model demonstrated insulin rate (odds ratio 0.736, 95% confidence interval, 0.549-0.985, p = 0.039) to be the only independent predictor of mortality among the measures of blood glucose control. CONCLUSION Nonsurvivors with TBI have significantly higher markers of IR (insulin rate and multiplier). Markers of glucose control (median glucose, hypoglycemic episodes, and the percentage of values in range) did not differ clinically among groups. Despite this stress IR, tight glycemic control appears possible and safe with low levels of hypoglycemic episodes in the TBI population.
Collapse
|
36
|
|
37
|
Schlienger JL, Pradignac A, Vinzio S, Luca F, Suna C, Grunenberger F, Goichot B. [Hyperglycemia in the critically ill: meaning and treatment]. Presse Med 2008; 38:562-70. [PMID: 19056206 DOI: 10.1016/j.lpm.2008.07.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2008] [Revised: 06/16/2008] [Accepted: 07/31/2008] [Indexed: 01/08/2023] Open
Abstract
Hyperglycemia is commun in critically ill patients without previously known diabetes. Hyperglycemia occurring in these patients is mainly a consequence of stress associated to complex glucose metabolism abnormalities which have deleterious effects on tissues and vascular function. Several epidemiologic and intervention studies had established that hyperglycemia is related to morbidity and mortality. Maintenance of normoglycemia with intensive insulin therapy seems to decrease morbidity and mortalities in severe acute illnesses. However the benefit of most of these intervention trials remain controversial mainly in stroke, myocardial infarction and severe sepsis. Moreover strict normoglycemia required to obtain an optimal benefit increases the risk of hypoglycaemia which may be particularly harmful in patients in critical state.
Collapse
Affiliation(s)
- Jean-Louis Schlienger
- Service de médecine interne et nutrition, Hôpital de Hautepierre, F-67098 Strasbourg Cedex, France.
| | | | | | | | | | | | | |
Collapse
|
38
|
Roberge MC, Messier C, Staines WA, Plamondon H. Food restriction induces long-lasting recovery of spatial memory deficits following global ischemia in delayed matching and non-matching-to-sample radial arm maze tasks. Neuroscience 2008; 156:11-29. [PMID: 18672030 DOI: 10.1016/j.neuroscience.2008.05.062] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2007] [Revised: 05/30/2008] [Accepted: 05/30/2008] [Indexed: 12/29/2022]
Abstract
Food restriction has been shown to be beneficial for a number of brain processes. In the current study, we characterized the impact of food restriction on hippocampal damage 70 days following ischemia. We assessed memory and cognitive flexibility of ad libitum fed (AL) and food-restricted (FR) animals using complex delayed non-matching- and matching-to-sample tasks in the radial arm maze. Our findings demonstrate that food restriction led to significant improvement of ischemia-induced memory impairments. FR ischemic animals rapidly reached comparable performance as both AL and FR sham animals in delayed-non-matching (win-shift) and matching (win-stay) radial arm maze tasks. They also made considerably fewer microchoices in the retention trials than AL ischemic animals. In contrast, AL ischemic rats showed persistent spatial memory impairments in the same paradigms. Assessment of basal and stress-induced corticosterone (CORT) secretion revealed no significant differences in baseline levels in AL and FR rats prior to or following global ischemia. However, FR animals showed a more pronounced attenuation of CORT secretion 45 min following restraint. Both FR and AL ischemic rats had comparable cell loss within CA1 and CA3 subfields of Ammon's horn (CA1 and CA3) at 70 days following reperfusion, although a trend toward increased CA3 cell survival was observed in FR ischemic rats. The functional sparing in the FR ischemic animals in the face of equivalent hippocampal cell loss suggests that food restriction somehow enhanced the efficacy of remaining hippocampal or extrahippocampal neurons following ischemia. In the current study, this phenomenon was not associated with diet- and or ischemia-related alterations of vesicular glutamate transporter 1 expression in various hippocampal regions although lower vesicular GABA transporter immunostaining was present in the CA1 stratum oriens and the CA3 stratum radiatum in FR sham and ischemic rats.
Collapse
Affiliation(s)
- M-C Roberge
- University of Ottawa, School of Psychology, 11, Marie Curie, Vanier Building Room 204, Ottawa, ON, Canada K1N 9A4
| | | | | | | |
Collapse
|
39
|
Affiliation(s)
- Michael T. McCormick
- From the Divisions of Clinical Neurosciences (M.T.M., K.W.M.) and Cardiovascular and Medical Sciences (M.R.W.), University of Glasgow; and the School of Clinical Medical Sciences (C.S.G.), Newcastle University, UK
| | - Keith W. Muir
- From the Divisions of Clinical Neurosciences (M.T.M., K.W.M.) and Cardiovascular and Medical Sciences (M.R.W.), University of Glasgow; and the School of Clinical Medical Sciences (C.S.G.), Newcastle University, UK
| | - Christopher S. Gray
- From the Divisions of Clinical Neurosciences (M.T.M., K.W.M.) and Cardiovascular and Medical Sciences (M.R.W.), University of Glasgow; and the School of Clinical Medical Sciences (C.S.G.), Newcastle University, UK
| | - Matthew R. Walters
- From the Divisions of Clinical Neurosciences (M.T.M., K.W.M.) and Cardiovascular and Medical Sciences (M.R.W.), University of Glasgow; and the School of Clinical Medical Sciences (C.S.G.), Newcastle University, UK
| |
Collapse
|
40
|
Nagamizo D, Tsuruta S, Matsumoto M, Matayoshi H, Yamashita A, Sakabe T. Tight glycemic control by insulin, started in the preischemic, but not postischemic, period, protects against ischemic spinal cord injury in rabbits. Anesth Analg 2007; 105:1397-403, table of contents. [PMID: 17959972 DOI: 10.1213/01.ane.0000281146.33391.69] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND It is not well established whether insulin protects against ischemic spinal cord injury. We examined the effects of a single dose of insulin that corrects mild hyperglycemia on the outcome after transient spinal cord ischemia in rabbits. METHODS We assigned rabbits to four groups (n = 8 in each); untreated control (C) group, preischemic insulin (Pre-I) group, preischemic insulin with glucose (GI) group (glucose concentrations were maintained at levels similar to the C group by the administration of glucose), and postischemic insulin (Post-I) group. Insulin (0.5 IU/kg) was administered 30 min before ischemia in the Pre-I and GI groups, and just after reperfusion in the Post-I group. Spinal cord ischemia was produced by occluding the abdominal aorta for 13 min. Neurologic and histopathologic evaluations were performed 7 days after ischemia. RESULTS The mean blood glucose concentration before ischemia in the Pre-I group (118 mg/dL) was significantly lower than in the other three groups (158-180 mg/dL) and those of 30 min after reperfusion in the Pre-I (92 mg/dL) and Post-I (100 mg/dL) groups were significantly lower than in the C (148 mg/dL) and GI (140 mg/dL) groups. The motor function score and number of normal neurons in the anterior lumbar spinal cord in the Pre-I group were significantly greater than in the other three groups. CONCLUSIONS These results suggest that a relatively small dose of preischemic insulin protects against ischemic spinal cord injury, and that the protective effects result from tight glycemic control before ischemia.
Collapse
Affiliation(s)
- Daisuke Nagamizo
- Department of Anesthesiology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
| | | | | | | | | | | |
Collapse
|
41
|
Drugs acting on SUR1 to treat CNS ischemia and trauma. Curr Opin Pharmacol 2007; 8:42-9. [PMID: 18032110 DOI: 10.1016/j.coph.2007.10.004] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2007] [Revised: 10/05/2007] [Accepted: 10/08/2007] [Indexed: 12/25/2022]
Abstract
Sulfonylurea receptor 1 (SUR1) is a molecule with more diverse and critically important functions than previously recognized. Long viewed simply as a subunit involved in formation of a subset of K(ATP) channels, accumulating evidence indicates that SUR1 is newly upregulated in CNS ischemia and injury and is surprisingly promiscuous in its association with different pore-forming subunits, which endow it with new roles not previously envisioned. In this review, we focus on the SUR1-regulated NC(Ca-ATP) channel, its emerging role in CNS ischemia and trauma, and the growing evidence from preclinical and clinical studies demonstrating the potential importance of block of SUR1 by sulfonylureas such as glibenclamide (glyburide) in conditions as seemingly diverse as stroke and spinal cord injury.
Collapse
|
42
|
Jiang Z, Kohzuki M, Harada T, Sato T. Glutathione suppresses increase of serum creatine kinase in experimental hypoglycemia. Diabetes Res Clin Pract 2007; 77:357-62. [PMID: 17321629 DOI: 10.1016/j.diabres.2007.01.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2006] [Revised: 11/10/2006] [Accepted: 01/10/2007] [Indexed: 10/23/2022]
Abstract
Inhibitory effects of reduced glutathione (GSH) on serum enzymes including alanine aminotransferase (AST), lactate dehydrogenase (LDH) and creatine kinase (CK) were investigated in the hypoglycemic rabbits. Hypoglycemia lasting for 60 min was induced by intravenous injection of insulin (10U/kg) and then recovered by intravenous glucose injection. Serum levels of ALT, AST, LDH and CK increased significantly (p<0.05) at 6h after the induction of hypoglycemia. Plasma GSH, oxidized glutathione (GSSG) and total glutathione (TGSH) began to increase significantly (p<0.05) at 1h after the insulin injection, and GSSG/TGSH ratio rose significantly (p<0.05) at 6h after the induction of hypoglycemia. GSSG contents and GSSG/TGSH ratio in quadriceps significantly increased during hypoglycemia. Administration of GSH significantly decreased plasma GSSG levels, GSSG/TGSH ratio (p<0.05) and suppressed the rise of serum enzymes induced by hypoglycemia. These results suggest that GSH administration may play a preventive role for increases of serum enzymes by experimental hypoglycemia.
Collapse
Affiliation(s)
- Zhongli Jiang
- Department of Rehabilitation Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| | | | | | | |
Collapse
|
43
|
Kunte H, Schmidt S, Eliasziw M, del Zoppo GJ, Simard JM, Masuhr F, Weih M, Dirnagl U. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007; 38:2526-30. [PMID: 17673715 PMCID: PMC2742413 DOI: 10.1161/strokeaha.107.482216] [Citation(s) in RCA: 130] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND AND PURPOSE The sulfonylurea receptor 1-regulated NC(Ca-ATP) channel is upregulated in rodent models of stroke with block of the channel by the sulfonylurea, glibenclamide (glyburide), significantly reducing mortality, cerebral edema, and infarct volume. We hypothesized that patients with type 2 diabetes mellitus taking sulfonylurea agents both at the time of stroke and during hospitalization would have superior outcomes. METHODS We reviewed medical records of patients with diabetes mellitus hospitalized within 24 hours of onset of acute ischemic stroke in the Neurology Clinic, Charité Hospital, Berlin, Germany, during 1994 to 2000. After exclusions, the cohort comprised 33 patients taking a sulfonylurea at admission through discharge (treatment group) and 28 patients not on a sulfonylurea (control group). The primary outcome was a decrease in National Institutes of Health Stroke Scale of 4 points or more from admission to discharge or a discharge National Institutes of Health Stroke Scale score of 0. The secondary outcome was a discharge modified Rankin Scale score < or =2. RESULTS No significant differences, other than stroke subtype, were observed among baseline variables between control and treatment groups. The primary outcome was reached by 36.4% of patients in the treatment group and 7.1% in the control group (P=0.007). The secondary outcome was reached by 81.8% versus 57.1% (P=0.035). Subgroup analyses showed that improvements occurred only in patients with nonlacunar strokes and were independent of gender, previous transient ischemic attack, and blood glucose levels. CONCLUSIONS Sulfonylureas may be beneficial for patients with diabetes mellitus with acute ischemic stroke. Further investigation of similar cohorts and a prospective randomized trial are recommended to confirm the present observations.
Collapse
Affiliation(s)
- Hagen Kunte
- Department of Neurology, Center for Stroke Research, Humboldt University, Berlin, Germany
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Arboix A. Potential impact of sulfonylureas in the outcome of type 2 diabetic patients with ischemic stroke. Stroke 2007; 38:2413-4. [PMID: 17673799 DOI: 10.1161/strokeaha.107.488361] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Abstract
Admission hyperglycemia complicates approximately one-third of acute ischemic strokes and is associated with a worse clinical outcome. Both human and animal studies have showed that hyperglycemia is particularly detrimental in ischemia/reperfusion. Decreased reperfusion blood flow has been observed after middle cerebral artery occlusion in acutely hyperglycemic animals, suggesting the vasculature as an important site of hyperglycemic reperfusion injury. This paper reviews biochemical and molecular pathways in the vasculature that are rapidly affected by hyperglycemia and concludes that these changes result in a pro-vasoconstrictive, pro-thrombotic and pro-inflammatory phenotype that renders the vasculature vulnerable to reperfusion injury. Understanding these pathways should lead to the development of rational therapies that reduce hyperglycemic reperfusion injury and thus improve outcome in this large subset of acute ischemic stroke patients.
Collapse
Affiliation(s)
- Sharyl R Martini
- Department of Neurology, Baylor College of Medicine and the Michael E DeBakey Veterans Affairs Medical Center Stroke Program, Houston, TX 77030, USA
| | | |
Collapse
|
46
|
Sutherland GR, Auer RN. Primary intracerebral hemorrhage. J Clin Neurosci 2006; 13:511-7. [PMID: 16769513 DOI: 10.1016/j.jocn.2004.12.012] [Citation(s) in RCA: 106] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2004] [Accepted: 12/15/2004] [Indexed: 01/15/2023]
Abstract
This article reviews the epidemiology, pathophysiology and management of primary intracerebral hemorrhage. In North American and European populations, 15% of strokes are due to intracerebral hemorrhage. Pathologically in hypertension, early arteriolar proliferation of smooth muscle is followed later by smooth muscle cell death and collagen deposition. This eventually leads to occlusion or ectasia of arterioles. The latter leads to Charcôt-Bouchard aneurysm formation and possible intracerebral hemorrhage. Amyloid deposition in the tunica media causes similar brittle arterioles. Fibrin globes in concentric spheres attempt to seal off the site of bleeding. But vasculopathy (either amyloid or hypertensive) inhibits the contractile capability of arterioles. The size of the final sphere of blood at cessation of bleeding determines the clinical spectrum, from asymptomatic to fatal. Since arteriolar bleeding is slower than arterial bleeding, several hours exist where intervention may be useful. While medical intervention is controversial, guidelines for blood pressure, intracranial pressure, glucose and seizure management exist. Surgical trials have tended to show no benefit. Recombinant factor VIIa is undergoing investigation as hemostatic therapy for intracerebral hemorrhage, to limit clot expansion and possibly also as a hemostatic adjunct to surgery.
Collapse
Affiliation(s)
- Garnette R Sutherland
- Department of Pathology and Laboratory Medicine, 3330 Hospital Drive NW, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | | |
Collapse
|
47
|
McGirt MJ, Woodworth GF, Brooke BS, Coon AL, Jain S, Buck D, Huang J, Clatterbuck RE, Tamargo RJ, Perler BA. Hyperglycemia independently increases the risk of perioperative stroke, myocardial infarction, and death after carotid endarterectomy. Neurosurgery 2006; 58:1066-73; discussion 1066-73. [PMID: 16723885 DOI: 10.1227/01.neu.0000215887.59922.36] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE Clinical and experimental evidence suggests that hyperglycemia lowers the neuronal ischemic threshold, potentiates stroke volume in focal ischemia, and is associated with morbidity and mortality in the surgical critical care setting. It remains unknown whether hyperglycemia during carotid endarterectomy (CEA) predisposes patients to perioperative stroke and operative related morbidity and mortality. METHODS The clinical and radiological records of all patients undergoing CEA and operative day glucose measurement from 1994 to 2004 at an academic institution were reviewed and 30-day outcomes were assessed. The independent association of operative day glucose before CEA and perioperative morbidity and mortality were assessed via multivariate logistic regression analysis. RESULTS One thousand two hundred and one patients with a mean age of 72 +/- 10 years (748 men, 453 women) underwent CEA (676 asymptomatic, 525 symptomatic). Overall, stroke occurred in 46 (3.8%) patients, transient ischemic attack occurred in 19 (1.6%), myocardial infarction occurred in 19 (1.6%), and death occurred in 17 (1.4%). Increasing operative day glucose was independently associated with perioperative stroke or transient ischemic attack (Odds ratio [OR], 1.005; 95% confidence interval [CI], 1.00-1.01; P = 0.03), myocardial infarction (OR, 1.01; 95% CI, 1.004-1.016; P = 0.017), and death (OR, 1.007; 95% CI, 1.00-1.015; P = 0.04). Patients with operative day glucose greater than 200 mg/dl were 2.8-fold, 4.3-fold, and 3.3-fold more likely to experience perioperative stroke or transient ischemic attack (OR, 2.78; 95% CI, 1.37-5.67; P = 0.005), myocardial infarction (OR, 4.29; 95% CI, 1.28-14.4; P = 0.018), or death (OR, 3.29; 95% CI, 1.07-10.1; P = 0.037), respectively. Median and interquartile range length of hospitalization was greater for patients with operative day glucose greater than 200 mg/dl (4 d [interquartile range, 2-15 d] versus 3 d [interquartile range, 2-7 d]; P < 0.05). CONCLUSION Independent of previous cardiac disease, diabetes, or other comorbidities, hyperglycemia at the time of CEA was associated with an increased risk of perioperative stroke or transient ischemic attack, myocardial infarction, and death. Strict glucose control should be attempted before surgery to minimize the risk of morbidity and mortality after CEA.
Collapse
Affiliation(s)
- Matthew J McGirt
- Department of Neurosurgery, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
Hyperglycemia is correlated with poor prognosis in ischemic strokes and also increases the risk of hemorrhagic transformation after thrombolysis. The toxicity of hyperglycemia, already well established in animals, is beginning to be clear for humans. On the other hand, the beneficial effect of insulin remains controversial in animals and has never been demonstrated in humans. Preliminary data, which suggest that the speed and quality of glycemic control may be decisive in the efficacy of treatment, merit testing in a randomized trial.
Collapse
Affiliation(s)
- Yves Samson
- Urgences Cérébrovasculaires, Groupe Hospitalier Pitié-Salpêtrière et Université Pierre et Marie Curie-Paris VI, Paris.
| | | | | | | | | |
Collapse
|
49
|
Abstract
PURPOSE OF REVIEW This article presents an overview of the most recent and important strategies to reduce secondary brain damage. RECENT FINDING There is currently no magic bullet available to protect the brain after neuronal injury. This is related to the complex pathophysiology of cerebral ischemia, which makes it unlikely that a single pharmacological intervention results in sustained neuroprotection. Analyses of clinical studies reveal that acute physiologic derangements (e.g. fever, hypertension and hypotension, hypoxemia, hypercapnia, hyperglycemia) are the most important predictors of unfavorable outcome after brain injury and have to be treated. The effectiveness of anesthetic agents to extend the ischemic tolerance of neurons has been demonstrated in experimental settings, but such benefits have not been demonstrated in humans. The effectiveness of osmodiuretics to decrease elevated intracranial pressure, a factor with relevance to outcome, has been demonstrated. Infusion of magnesium in patients with subarachnoidal hemorrhage can reduce the occurrence of delayed ischemia caused by cerebrovascular spasm. The prophylactic administration of glucocorticoids should be avoided. While the positive effects of chronic administration of statins to reduce the incidence of stroke has been demonstrated in several clinical studies, the protective effect of acute administration of statins after a cerebral insult has do be defined. SUMMARY Control of physiological variables, avoidance of hyperthermia, intensive control of plasma glucose concentrations, use of anesthetic agents and osmodiuretics to control intracranial hypertension and the possible prophylactic administration of magnesium in patients at risk of vasospasm and of statins in patients with cerebrovascular risk factors are currently the most important strategies to reduce neuronal injury.
Collapse
Affiliation(s)
- Serge C Thal
- Department of Anesthesiology, Johannes Gutenberg University, Mainz, Germany
| | | | | |
Collapse
|
50
|
Strong AJ, Boutelle MG, Vespa PM, Bullock MR, Bhatia R, Hashemi P. Treatment of Critical Care Patients with Substantial Acute Ischemic or Traumatic Brain Injury. Crit Care Med 2005; 33:2147-9; author reply 2149. [PMID: 16148510 DOI: 10.1097/01.ccm.0000179029.95415.51] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|